Related Experiment Video
Updated: Sep 28, 2026
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Cell transplantation in non-ischemic dilated cardiomyopathy. A novel biological approach for ventricular restoration
Nobuhisa Ohno1, Paul W M Fedak, Richard D Weisel
1Toronto General Hospital, Division of Cardiac Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Insights
Cell transplantation shows promise in treating dilated cardiomyopathy (DCM) by preserving heart function and preventing left ventricular (LV) dilatation. Further research is needed for clinical application.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell Biology
Background:
- Dilated cardiomyopathy (DCM) presents a significant healthcare challenge with high mortality rates.
- Current medical and surgical treatments for DCM offer limited success in preventing left ventricular (LV) dilatation.
Purpose of the Study:
- To investigate the efficacy of muscle cell transplantation in a hamster model of DCM.
- To assess the potential of cell transplantation as a novel therapeutic strategy for DCM.
Main Methods:
- Transplantation of heart cells and smooth muscle cells into hamsters with DCM.
- Evaluation of cell survival, impact on LV dilatation, wall thinning, and cardiac function.
- Ongoing studies focus on optimal cell types, transplantation timing, and cryopreservation.
Main Results:
- Transplanted cells survived in the host myocardium.
- Cell transplantation suppressed LV dilatation and wall thinning.
- Preservation of cardiac function was observed post-transplantation.
Conclusions:
- Muscle cell transplantation represents a potential clinically applicable biological therapy for progressive DCM.
- Further investigation into the molecular and cellular mechanisms underlying cell transplantation benefits is warranted for future clinical use.
Objective:
With a rising incidence, dilated cardiomyopathy (DCM) is regarded as a major health care concern. Although both medical therapy and novel surgical treatments have been applied to treat DCM, the effects of preventing left ventricular (LV) dilatation are limited, and the mortality rate associated with the disease remains high. Thus novel management strategies for improved treatment of DCM are awaited.
Methods:
Researchers have found that, in models of regional ventricular dysfunction, transplanted cells induced a profound biological phenomenon that restored contractile function and prevented ventricular dilatation. We have investigated muscle cell transplantation in hamsters with DCM, and have found that heart cells and smooth muscle cells survived in the host myocardium after transplantation, which suppressed LV dilatation and wall thinning, and preserved heart function. Our current studies are focusing on the clinical applicability of these encouraging early findings by evaluating the optimal cell types, the timing of transplantation, and cryopreservation as cell storage. Concurrently, we are investigating the influence of cell transplantation on myocardial remodeling in order to outline the mechanism of benefit afforded by donor cell engraftment. We believe that the timing of cell transplantation with respect to the progression of the underlying disease is critical in preventing ventricular thinning, dilation and preserving cardiac function.
Conclusions:
This novel approach can be a clinically applicable biological therapy for patients with progressive DCM. More studies to uncover the specific molecular and cellular effects of cell transplantation on the host myocardium are necessary for future clinical application.
